Vabysmo (faricimab-svoa)
Solutions
Pharma Products
See all Pharma Products

Vabysmo (faricimab-svoa) is the first bispecific antibody designed for the eye. It targets and inhibits two disease pathways linked to a number of vision-threatening retinal conditions by neutralising angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision loss by destabilising blood vessels, causing new leaky blood vessels to form and increasing inflammation. By blocking both pathways involving Ang-2 and VEGF-A, Vabysmo is designed to stabilise blood vessels.

Currently, Vabysmo is approved for the treatment of neovascular or “wet” age-related macular degeneration and diabetic macular edema in the United States and Japan.